Home > Gastroenterology > ECCO 2022 > Short-Term and Long-Term Treatment Results > Ozanimod treatment shows maintained response in ulcerative colitis

Ozanimod treatment shows maintained response in ulcerative colitis

Presented By
Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy
Conference
ECCO 2022
Trial
Phase 3, True North
Ozanimod demonstrated long-term durability of efficacy in participants with active ulcerative colitis (UC). Moreover, results from the open-label, extension study of the phase 3 True North trial did not display new safety issues associated with the long-term use of ozanimod. Ozanimod is an S1P receptor modulator, approved for the treatment of patients with moderately to severely active UC based on the 52-week results of the True North trial (NCT02435992) [1]. An open-label extension study was initiated to assess the long-term efficacy of ozanimod [2]. In total, 823 participants entered the open-label extension study of the True North trial, of whom 64%, 34%, and 14% completed the week 46, week 94, and week 142 time points, respectively. Lack of efficacy (21%) and withdrawal by subject (13%) were the main reasons for treatment discontinuations. Prof. S...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on